Last updated: June 15, 2026
Apotex Inc v. Daiichi Sankyo, Inc. (1:15-cv-03695) Litigation Summary and Patent/Exclusivity Analysis
Executive summary: Apotex’s suit against Daiichi Sankyo in 1:15-cv-03695 is a federal Hatch-Waxman patent dispute in which Apotex challenged Daiichi’s Orange Book-listed patent protections for a Daiichi Sankyo product and sought approval to market a generic. The case record centers on Paragraph IV-style patent validity and non-infringement theories, with postures focused on whether the asserted Orange Book patents could withstand generic infringement and invalidity challenges. The litigation history, settlement status, and the precise patents asserted determine the remaining risk of generic launch and the strength of Daiichi’s IP estate.
What is the case caption and docket structure for Apotex v. Daiichi Sankyo 1:15-cv-03695?
Case identification
- Court: U.S. District Court (federal)
- Case number: 1:15-cv-03695
- Parties: Apotex Inc. (plaintiff/generic challenger) vs. Daiichi Sankyo, Inc. (defendant/brand)
- Nature: Patent litigation tied to FDA approval under the Hatch-Waxman Act (Orange Book patent challenges)
Why the caption matters for scope
- In Hatch-Waxman cases, the parties and the docket number typically map to a specific ANDA and a specific FDA application reference product.
- The specific drug name, strength, and dosage form are usually encoded in the complaint’s ANDA/labeling allegations and the Orange Book patent list attached to the complaint.
What patents were at issue and what Orange Book protections were challenged?
How the litigation typically frames the patent set
- The complaint in Hatch-Waxman infringement actions usually identifies:
- Asserted Orange Book patents (often formulation, method-of-use, composition, or manufacturing-related)
- Each patent’s asserted basis for infringement (often with product-by-patent infringement charts)
- Apotex’s counterclaims for invalidity (anticipation, obviousness, enablement, written description, indefiniteness) and/or non-infringement
Key analysis points that drive outcomes
- Claim construction: Whether the court construes asserted claim terms narrowly enough to create a non-infringement pathway for the generic.
- Validity defenses: Whether prior art or statutory grounds defeat novelty/obviousness or fail compliance requirements.
- If “no injunction” settlement occurs: the case may still conclude with a license or an agreed launch date, changing exclusivity economics even if patents are not fully invalidated.
What are the main Hatch-Waxman legal issues in Apotex v. Daiichi Sankyo?
Typical issues in this docket type
- Paragraph IV challenge timing and jurisdiction
- Apotex’s standing usually arises from filing an ANDA with a certification challenging one or more Orange Book patents.
- Infringement
- Apotex argues its proposed generic does not meet one or more limitations of asserted claims.
- Invalidity
- Apotex asserts asserted patents are invalid under Title 35 theories, commonly including:
- lack of novelty (35 USC 102)
- obviousness (35 USC 103)
- inadequate written description/enablement (35 USC 112)
- indefiniteness (35 USC 112(b))
- Exclusionary relief
- The brand seeks an injunction to prevent FDA approval and commercial launch.
Outcome drivers
- Courts frequently decide on:
- claim construction first
- then infringement and validity on the construed record
- or on summary judgment if the factual and legal issues are clean
When does the litigation timeline start, and what does it imply for exclusivity?
Docket timing
- The case number indicates a mid-2015 filing: 2015-09 style docketing (1:15-cv-03695).
- The start date typically lines up with an ANDA patent certification and a statutory 45-day notice period.
Exclusivity inference
- If the brand’s patents were actively listed and asserted, this litigation likely sits inside:
- the window where the FDA can approve but cannot permit commercial marketing until patent litigation resolves, depending on procedural posture
- or a window where a settlement sets an earlier market date than would otherwise occur
How does Paragraph IV certification map to generic entry risk in this case?
Risk framework for Apotex
- If Apotex prevailed on non-infringement or invalidity for all asserted patents:
- FDA approval could proceed toward a “at-risk” commercial launch date (subject to any stay or injunction)
- If Apotex lost:
- the generic launch is blocked until expiration of the asserted patents or until a later successful litigation or re-filing strategy
Risk framework for Daiichi
- If Daiichi prevailed on all asserted claims:
- generic entry is deferred until patent expiration
- If only some patents survive:
- generic entry can occur at a date tied to the last surviving patent expiration or settlement trigger
What is the “strength” of Daiichi Sankyo’s patent estate in this dispute?
Strength is measured by what the court allows
- Strongest estate signals:
- claims survive construction
- validity defenses fail
- injunction granted or settlement aligns with long-term protection
- Weaker estate signals:
- invalidation of key claims
- narrowing claim constructions that avoid infringement
- settlement with early launch dates
Litigation-derived indicators
- Whether the court issued dispositive rulings (summary judgment, claim construction, Daubert/Markman outcomes)
- Whether any patents were dropped during the case (often occurs when certain claims are mooted by amendment or court rulings)
- Whether the parties reached a consent judgment or a settlement that fixes a launch date
How does settlement affect launch dates and damages exposure?
Common settlement structures in Hatch-Waxman
- “Consent judgment” with an agreed patent list and carve-outs
- License-back allowing market entry in exchange for a royalty
- Stipulated injunction that ends on a defined date
- “Carve-out by exclusivity” where one party agrees not to assert certain patents or to treat certain changes as non-infringing
Business impact
- Settlement converts a litigation uncertainty into:
- a predictable launch timetable
- a known payment or royalty stream
- or a fixed design-around boundary that blocks additional generic entrants
What does FDA and Orange Book status typically look like for this type of case?
Orange Book status needed for market sequencing
- If Daiichi listed multiple patents:
- each patent may have different expiration dates
- some patents may be only eligible for enforcement against launch, not against individual manufacturing steps
Regulatory pathway
- Apotex likely pursued an ANDA certification tied to the relevant Orange Book patents.
- Post-litigation, the FDA status typically becomes:
- approval pending resolution (if injunction applies)
- or approval allowing launch when the court order or settlement permits
What generic entry risks exist if Apotex loses in this case?
Post-loss risk
- A loss commonly creates:
- an immediate bar to launch for the involved strengths/forms under the same infringement theory
- a blocking effect for other generics using similar formulations or methods
- Design-around risk depends on:
- whether Daiichi’s surviving claims are composition-level or narrow formulation/method claims
- whether alternatives can avoid a limitation without changing bioequivalence or regulatory acceptance
Competitive knock-on effects
- Even if Apotex cannot launch, other ANDA filers may:
- challenge the remaining patents
- file separate designs to reach a non-infringing product profile
- or wait for expiration rather than litigate
Which companies were likely involved beyond Apotex and Daiichi?
Typical multi-party patterns
- Hatch-Waxman cases sometimes include:
- other ANDA filers as co-plaintiffs or intervenors
- related corporate entities as plaintiffs/defendants for specific responsibilities
- But for 1:15-cv-03695, the case caption given only identifies:
- Apotex Inc.
- Daiichi Sankyo, Inc.
- Third-party involvement is dictated by the complaint and the docket events.
What is the litigation posture: dismissed, stayed, or decided?
What determines this posture
- Procedural outcomes are reflected in:
- docket entries for motions (transfer, dismiss, stay, summary judgment)
- claim construction orders
- final judgment or consent orders
- any appellate notices if outcomes were appealed
Why it matters
- If stayed, launch risk is tied to ongoing appeals or parallel cases involving related patents.
- If decided, launch is tied to the specific patent(s) that survive and the controlling injunction.
Key case outcomes, dates, and dispositive events (required for decision-grade analysis)
Missing for this docket-only prompt
- The litigation summary and analysis requested requires case-specific data:
- asserted patent numbers
- court’s Markman/claim construction holdings
- dispositive rulings (summary judgment grant/denial)
- settlement date and terms (if any)
- final judgment and any injunction dates
- Those facts cannot be produced accurately from the docket number alone.
Key Takeaways
- 1:15-cv-03695 is a Hatch-Waxman-style patent litigation between Apotex Inc. and Daiichi Sankyo, Inc., centered on Orange Book patent challenges tied to an ANDA pathway.
- The commercial impact hinges on which Orange Book patents were asserted, the court’s claim construction, and any settlement terms fixing a launch date.
- Decision-grade analysis requires the docket’s specific patent list and procedural outcomes; without those entries, the litigation cannot be summarized into actionable strength, exclusivity, or launch timing conclusions.
FAQs
- What does a Paragraph IV certification mean for generic launch timing in Hatch-Waxman cases like 1:15-cv-03695?
- How do claim construction outcomes typically influence infringement findings in ANDA patent litigations?
- What factors determine whether a settlement sets a fixed design-around product profile?
- How does an appellate stay change commercial launch risk after a district court decision?
- What commercial damages exposure models are used when an injunction is modified or lifted later in the case?
References
- (No citable sources provided in the prompt.)
